Podcasts about Atopic dermatitis

Today we are bringing you a conversation on how topical therapies can effectively manage atopic dermatitis. Brian Keegan, MD, PhD, FAAD, a dermatologist with Princeton Dermatology, spoke with Alexa Hetzel, MS, PA-C, physician assistant with Schweiger Dermatology Group; Vikash D. Oza, MD, director of pediatric dermatology at NYU Langone; and Amy Spizuoco, DO, FAOCD, dermatologist and dermatopathologist at True Dermatology. In addition to discussing the clinical benefits and impact on patient outcomes of using topical therapies for atopic dermatitis, the panelists explored how health economics research informs treatment decisions by demonstrating the cost-effectiveness and accessibility of topical therapies. The panel also analyzed the potential health care cost savings and resource optimization achieved through strategic use of topical treatments and atopic dermatitis management.

Recap and review the top pearls from episodes #35 Atopic Dermatitis, #82 Tinea, and #95 Acne with a few members of our production team! It's Fables from the Cribside! (FFTC), our series providing a rapid review of recent Cribsiders episodes for your spaced learning.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into several significant shifts in the industry, marked by scientific advancements, regulatory changes, and strategic corporate maneuvers.Starting with a major acquisition, Novartis has strategically purchased Avidity Biosciences, a San Diego-based biotech company specializing in muscular dystrophy treatments, for a striking $12 billion. This substantial investment underscores Novartis's dedication to expanding its neuroscience portfolio. Avidity's innovative RNA-based therapies show great promise for treating neuromuscular diseases, highlighting a broader industry trend where large pharmaceutical companies are investing heavily in late-stage biotech firms to bolster their pipelines with cutting-edge technologies. Such moves are pivotal as they align with the growing emphasis on precision medicine and the development of novel therapeutic options for conditions with limited existing treatments.In other acquisition news, Eli Lilly has expanded its gene therapy portfolio through acquiring Adverum Biotechnologies for up to $262 million. This acquisition is expected to bolster Eli Lilly's position in the gene therapy space, particularly in ophthalmology. Gene therapy offers transformative potential by directly addressing underlying genetic causes of diseases, with Adverum's focus on ophthalmic conditions potentially offering innovative solutions for unmet medical needs in eye-related disorders. The acquisitions by Novartis and Eli Lilly reflect broader trends within the pharmaceutical industry where companies actively seek to diversify their pipelines through mergers and acquisitions. These transactions emphasize strategic incorporation of advanced biotechnologies such as RNA therapeutics and gene therapy into development portfolios aiming to deliver breakthroughs in patient care.On the regulatory front, Bayer has achieved a milestone with the U.S. FDA approval of Lynkuet (elinzanetant), a nonhormonal medication designed to manage menopause symptoms. This approval represents a significant step forward in providing alternative treatment options to a traditionally hormone-reliant segment, emphasizing the industry's shift towards diversifying therapeutic solutions and addressing unmet medical needs. This move highlights continuous efforts to address women's health issues through new pharmacological interventions.Meanwhile, Merck's Winrevair has received an updated FDA label following successful results from the Phase 3 Zenith trial. This label expansion is anticipated to enhance its market position, potentially propelling Winrevair to blockbuster status. These developments highlight the critical role of rigorous clinical trials in validating drug efficacy and safety, which ultimately influence regulatory decisions and market dynamics.BridgeBio has also made headlines with its successful Phase 3 trial for a rare disease candidate. By demonstrating significant improvements in clinical outcomes and biomarkers, BridgeBio is poised to file for FDA approval. This reflects an increasing focus on precision medicine within the industry, particularly in addressing rare and genetic disorders.In diabetes management news, Innovent and Eli Lilly's mazdutide has outperformed Novo Nordisk's semaglutide in a head-to-head study focused on glucose regulation and weight loss. As a GLP-1/glucagon dual receptor agonist, mazdutide offers broader therapeutic effects, showcasing the competitive landscape in metabolic disorders where novel mechanisms are vying for superiority.Regulatory activities remain pivotal, as demonstrated by Syndax receiving a second indication for its leukemia drug Revuforj. Such expansions underscore the importance of ongoing clinical research and regulatory engagement in maximizing a drug's therapeutic reach.NSupport the show

This podcast is published open access in Dermatology and Therapy and is fully citeable. You can access the original published podcast article through the Dermatology and Therapy website and by using this link:https://link.springer.com/article/10.1007/s13555-025-01551-7. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for October 5-11, 2025: 1. FDA Approves Roflumilast (Zoryve) Cream 0.05% for Atopic Dermatitis in Children Aged 2-5 Years The FDA approved roflumilast cream 0.05% for mild to moderate atopic dermatitis in children aged 2–5 years, expanding Arcutis' roflumilast portfolio. 2. Nerandomilast Nets First New FDA Approval for Idiopathic Pulmonary Fibrosis in Over 10 Years Nerandomilast became the first newly approved therapy for idiopathic pulmonary fibrosis in over a decade, offering a well-tolerated option that slows lung function decline. 3. LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Long-term data confirmed mirikizumab provides durable clinical, endoscopic, and quality-of-life benefits for ulcerative colitis up to four years, even in patients who failed prior advanced therapy. 4. Bax24: Baxdrostat Achieves Primary Endpoint in Treatment-Resistant Hypertension Baxdrostat met its primary endpoint in a phase 3 trial for treatment-resistant hypertension, supporting its potential role as a new option for difficult-to-control blood pressure. 5. Topical Bimiralisib Shows 92% Clearance Rate for Patients with Actinic Keratosis  Phase 2 data showed topical bimiralisib achieved high lesion clearance with favorable tolerability in patients with actinic keratosis.

Tom Lewis, DVM, DACVD is back on the podcast! Last year, Dr. Lewis joined the podcast last year to discuss the release of Zenrelia. One year later, he is back to discuss his experience with having this medication for a year and the relief it has provided for hundreds of his canine patients. Also, we discuss the recent change to the US boxed label warning which removed the vaccine induced disease portion of the label.Learn more on this week's episode of The Derm Vet podcast!Studies mentioned in podcast: Recent study regarding vaccine booster response in dogs receiving Zenrelia: Fent, G.M., Jacela, J., Plazola-Ortiz, R. et al. Immunologic response to first booster vaccination in dogs treated with zenrelia™ (ilunocitinib tablets) at up to three times the recommended therapeutic dose compared to untreated controls. BMC Vet Res 21, 481 (2025). https://doi.org/10.1186/s12917-025-04929-zRecent study regarding safety of Zenrelia: S. Forster, C. M. Trout, S. Despa, A. Boegel, D. Berger, and S. King, “ Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial,” Veterinary Dermatology (2025): 1–13, https://doi.org/10.1111/vde.70009.Timestamps00:00 Intro02:46 Zenrelia box label warning change08:14 What does the box label warning change mean and why it's only in the US?12:10 Looking at every patient as an individual17:00 How comfortable do you feel using Zenrelia long-term?22:14 Outro

This episode is sponsored by Elanco Animal Health On this episode of The Vet Blast Podcast presented by dvm360, Adam Christman, DVM, MBA, and Joya Griffin, DVM, DACVD, talk about how important it is for general practitioners to control pruritus quickly to retain client relationships, treatment approaches based on the severity and seasonality, and more.  You can watch the video version of this podcast on dvm360.com!

The recent expansion of the topical ruxolitinib approval to include pediatric patients aged 2 to 11 years with atopic dermatitis (AD) provides the first JAK inhibitor therapy option for this young population. In this episode, "Management of Atopic Dermatitis with JAK Inhibitors: A Pediatric to Geriatric Perspective," expert dermatologists, Christopher Bunick, MD, PhD and Karan Lal, DO discuss: Importance of JAK/STAT signaling in AD and the role of JAK inhibition in the future of dermatology Long-term safety of topical therapies for chronic AD Topline efficacy safety data from the phase 3 TRuE-AD3 clinical trial Shifting the paradigm of topical AD care across patient populations

Are you talking about quality of life with your patients with atopic dermatitis (AD)? Credit available for this activity expires: 9/30/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/atopic-dermatitis-its-more-than-skin-deep-2025a1000q26?ecd=bdc_podcast_libsyn_mscpedu

How comfortable are you with using JAK inhibitors in your practice? Credit available for this activity expires: 9/30/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/atopic-dermatitis-balancing-act-exploring-safety-and-2025a1000q2c?ecd=bdc_podcast_libsyn_mscpedu

Simplify pediatric eczema regimens with once-daily, nonsteroidal treatments. See what's making a difference for young patients and families. Credit available for this activity expires: 9/25/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/framing-future-topical-therapies-atopic-dermatitis-2025a1000p2a?ecd=bdc_podcast_libsyn_mscpedu

Zelma Chiesa Fuxench, MD, MSCE, FAAD interviewed by Carmen Castilla, MD, FAAD

Dr. Carole Keim welcomes pediatric dermatologist Dr. Teresa Wright, MD, to the podcast to talk about baby skin care, birthmarks, eczema, and anything to watch out for with a baby's skin that could potentially be dangerous. Dr. Wright works at Le Bonheur Children's Hospital in Memphis, Tennessee and is also faculty at the University of Tennessee Medical Center. She shares her journey into pediatric dermatology and explores all manner of common skin concerns, conditions, and questions regarding infants and their skin care with Dr. Keim, based on a wealth of experience and knowledge. Dr. Keim and Dr. Wright open by addressing the little pink or red spots in the middle of a newborn's forehead that are sometimes called angel kisses. The medical term is nevus simplex, and Dr. Wright assures listeners that they're nothing to worry about and will fade over time. They discuss types of newborn skin rashes, such as transient neonatal pustular melanosis, which are normal, before addressing conditions that might need a pediatrician's attention. Baby moles are explained in detail, atopic dermatitis or eczema is described, and Dr. Wright offers insight on how to mitigate or improve child skin dryness, along with tips on avoiding exposure to known irritants and allergens. This episode is full of facts and advice on infant skin, offering a practical guide to what is normal and what might need additional attention.Dr. Teresa Wright, MD:Dr. Wright attended medical school at the University of Massachusetts in Worcester, Massachusetts. She went on to complete a residency in pediatrics at the University of Massachusetts Medical Center. Subsequently, she completed a dermatology residency at the University of Kansas Medical Center and a fellowship in pediatric dermatology at Children's Mercy Hospitals and Clinics in Kansas City, Missouri. She joined the dermatology faculty at Baylor College of Medicine and Texas Children's Hospital (TCH) in January of 2009. In January of 2012, she was promoted to Section Chief of Pediatric Dermatology at TCH. She also served as Co-Director of the Vascular Anomalies Program at TCH from October 2011 through March of 2015. In July of 2015, she returned to her hometown of Memphis, TN to join the dermatology faculty at the University of Tennessee and establish a pediatric dermatology division at LeBonheur Children's Hospital. She has special interests and expertise in the diagnosis and management of hemangiomas and other vascular lesions, as well as pigmented lesions and pediatric melanoma. She is board-certified in pediatric dermatology, dermatology, and pediatrics. She is a member of the American Academy of Dermatology, the American Academy of Pediatrics, and the Society for Pediatric Dermatology.Dr. Wright has special interests and expertise in the diagnosis and management of hemangiomas and other vascular lesions, as well as pigmented lesions and pediatric melanoma.__ Resources discussed in this episode:The Holistic Mamas Handbook is available on AmazonThe Baby Manual is also available on Amazon__Contact Dr. Carole Keim, MDlinktree | tiktok | instagramContact Dr. Teresa Wright, MDwebsite | linkedin

Looking to go molecule deep in atopic dermatitis? We've got just the expert. This week, we're joined by Dr. Christopher Bunick as he brings structural biology into the atopic dermatitis discourse. Listen in as he discusses cytokines, itch, and the new definition of “skin clearance.” Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com.   Christopher Bunick, MD PhD is an Associate Professor of Dermatology at Yale School of Medicine in the Department of Dermatology. He specializes in general medical dermatology and dermatologic surgery. He also performs unique dermatologic research studying the three-dimensional structures of skin-related proteins using x-ray crystallography and cryo-electron microscopy. He completed medical internship, dermatology residency, and a dermatology research fellowship (mentored by Nobel Laureate Dr. Thomas A. Steitz) at Yale School of Medicine. Chris' research has pioneered a new focus in dermatology on fundamental biochemistry and structural biology, particularly connecting the atomic resolution mechanisms of action of a therapeutic to its clinical performance and safety.   Sponsored by: LEO Pharma Visit LEO Pharma website for more information. 

Do you struggle with helping pet owners understand the medical information about their pet's atopic dermatitis diagnosis or to comply with the treatment plan you've created to manage it? In this VetFolio Voice podcast episode, we go “beyond the itch” and chat about effective client communication when it comes to atopic dermatitis. We explore how complicated and nuanced this condition tends to be, illustrating why effective, informative and empathetic communication with clients is so important. Dr. Lancellotti tells Dr. Cassi how she designs her discharges to give clients a clear breakdown of the management plan and the function of each therapeutic recommendation. They delve into how additional tools can be useful, such as pre-written snippets and templates about atopic dermatitis, as well as providing other sources of information, including owner-facing podcasts, to help get information into owner's hands and help answer their questions in the most efficient way possible.

Summary In this truncated replay from a session at the 2025 SF Derm Annual Conference, Dr. Lawrence Eichenfield discusses the latest advancements in the treatment of atopic dermatitis, focusing on new topical and systemic therapies, the role of corticosteroids, and the evolving perspectives on patient care. He highlights the importance of understanding both the benefits and concerns associated with various treatments, including the impact of media on patient perceptions. Takeaways - We have new topical agents for atopic dermatitis. - Topical corticosteroids are like hammers for eczema. - Topical steroid addiction is a real concern. - We have lots of options for atopic dermatitis. - New non-steroidals are being approved for younger patients. - Dupilomab shows promise in remission data. - Topical care remains a cornerstone of treatment. - We need to defend topical corticosteroids. - Long-term safety data is crucial for new therapies. - Patients often fear topical steroid withdrawal. Chapters 00:00 - Introduction to Atopic Dermatitis Innovations 02:46 - Emerging Therapies for Atopic Dermatitis 04:33 - Topical Corticosteroids: Benefits and Concerns 08:30 - Understanding Topical Steroid Withdrawal 08:46 - New Non-Steroidal Treatments for Atopic Dermatitis

This podcast is published open access in Dermatology and Therapy and is fully citeable. You can access the original published podcast article through the Dermatology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s13555-025-01491-2. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Approximately 31 million people in the U.S., or 10% of the population, live with some form of eczema. But what are the different types of eczema, and why do certain types affect some people more than others? We spoke with Candrice R. Heath, MD, FAAP, FAAD, adult and pediatric dermatologist, about the eczema umbrella, treatment options, the surprising role of lifestyle factors like stress and sleep, the importance of tracking your triggers, and how to effectively partner with your doctor when it comes to managing your skin.See omnystudio.com/listener for privacy information.

Un nouvel épisode du Pharmascope est disponible! Dans ce 161e épisode, Nicolas et Isabelle reçoivent une nouvelle invitée pour discuter de nouveautés pharmacothérapeuthiques: le fezolinetant et roflumilast topique! Les objectifs pour cet épisode sont les suivants: Résumer les bénéfices et les risques associés à ces nouvelles thérapies. Expliquer les avantages et les inconvénients de ces thérapies. Discuter de la place des nouvelles thérapies dans l'arsenal thérapeutique Ressources pertinentes en lien avec l'épisode  FezolinetantNappi RE et coll. Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2). Menopause. 2024 Jun 1;31(6):512-521. Lederman S et coll. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023 Apr 1;401(10382):1091-1102. Johnson KA et coll. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. J Clin Endocrinol Metab. 2023 Jul 14;108(8):1981-1997. Ruan X et coll. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I). J Int Med Res. 2024 May;52(5):3000605241247684. Schaudig K et coll. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ. 2024 Nov 18;387:e079525. Douxfils J, Boretti E, Beaudart C, Dogné JM. Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies. Adv Ther. 2025 Aug;42(8):4089-4091. Roflumilast topiqueLebwohl MG et coll. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials. JAMA. 2022 Sep 20;328(11):1073-1084. Simpson EL et coll. Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials. JAMA Dermatol. 2024 Nov 1;160(11):1161-1170. Blauvelt A et coll. Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial. J Am Acad Dermatol. 2024 May;90(5):986-993.

In this episode, Daniel C. Butler, MD, and Shawn G. Kwatra, MD, discuss the practical considerations for using IL-13 inhibitors to treat patients with moderate to severe atopic dermatitis, including:Patient candidacy considerationsTreatment advancement strategies that go beyond topical therapiesThe importance of patient-centered care that address patients' fears and needsA detailed patient case to highlight take home pointsPresenterDaniel C. Butler, MD​Assistant Dean Student Affairs​University of Arizona College of Medicine – Tucson​Tucson, ArizonaShawn G. Kwatra, MD​Dr. Joseph W. Burnett Endowed Professor and Chair ​Department of Dermatology​University of Maryland School of Medicine​Baltimore, MarylandProgram page:https://bit.ly/4kTP04D

In this episode, Andrew F. Alexis, MD, MPH; Daniel C. Butler, MD; and Shawn G. Kwatra, MD, discuss IL-13 inhibition for treating patients with moderate to severe atopic dermatitis (AD), including:The available biologic therapies that specifically target IL-13Where these agents fall in the 2024 American Academy of Dermatology treatment algorithmHow these agents compare to other AD therapies like topical corticosteroids and oral JAK inhibitorsA detailed patient case to highlight take home pointsPresenterAndrew F. Alexis, MD, MPH​Professor of Clinical Dermatology​Weill Cornell Medical College ​New York, New YorkDaniel C. Butler, MD​Assistant Dean Student Affairs​University of Arizona College of Medicine – Tucson​Tucson, ArizonaShawn G. Kwatra, MD​Dr. Joseph W. Burnett Endowed Professor and Chair ​Department of Dermatology​University of Maryland School of Medicine​Baltimore, MarylandProgram page:https://bit.ly/4kTP04D

In this episode, Andrew F. Alexis, MD, MPH, and Daniel C. Butler, MD, discuss the immunopathogenesis and role of IL-13 in atopic dermatitis (AD), including:Contributors to epidermal barrier dysfunction (eg, environmental triggers)IL-13 as a key cytokine in AD pathogenesisTargeted AD therapies that inhibit IL-13A detailed patient case to highlight take-home pointsPresenterAndrew F. Alexis, MD, MPH​Professor of Clinical Dermatology​Weill Cornell Medical College ​New York, New YorkDaniel C. Butler, MD​Assistant Dean Student Affairs​University of Arizona College of Medicine – Tucson​Tucson, ArizonaProgram page: https://bit.ly/4kTP04D

Emma Guttman-Yassky, MD, PhD - Atopic Dermatitis and the 0X40 Pathway: Understanding the Therapeutic Potential of OX40 Inhibition in Atopic Dermatitis

Emma Guttman-Yassky, MD, PhD - Atopic Dermatitis and the 0X40 Pathway: Understanding the Therapeutic Potential of OX40 Inhibition in Atopic Dermatitis

In this episode Jennifer Schoch, MD, FAAD, FAAP, discusses updated guidelines for the diagnosis and treatment of atopic dermatitis or eczema. Hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, also speak with Esli Osmanlliu, MD, and medical student Nik Jaiswal about the accuracy of large language models in pediatric and adult medicine. For resources go to aap.org/podcast.

CME credits: 1.00 Valid until: 11-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/taking-action-in-moderate-to-severe-pediatric-atopic-dermatitis-patient-and-caregiver-centered-approaches-to-improve-outcomes/35848/ On-demand webcast of expert faculty presentation on improving outcomes for pediatric patients with atopic dermatitis, including strategies for implementing systemic therapies and using patient-reported/caregiver-reported outcomes to deliver person-centered care.=

A young woman is on a mission to shed light on the harsh realities of living with Atopic Dermatitis. 19-year-old Alicja Stachurska from Lisdoonvarna, has launched an online awareness campaign through Instagram after years of struggling with the debilitating skin condition, also known as eczema. From sleepless nights to a visit to the A&E, Alicja says she reached a breaking point — and decided to take action. Her page, malinka_eczema, shares personal updates, practical advice, and candid reflections with the goal of supporting others in similar situations. Clare FM's Ewelina Szybinska caught up with Alicja to hear more about her journey — and why she believes raw honesty is key to healing... Check out Alicja's instagram here: https://www.instagram.com/malinka_eczema/ Photo(C): Alicja Stachurska

In today's VETgirl online veterinary CE podcast, we talk to Dr. Thomas Lewis, DACVD, paid consultant for Elanco Animal Health, about managing atopic dermatitis in 2025. In veterinary medicine, we see a lot of atopic dermatitis in clinical practice. Stay up-to-date in managing atopic dermatitis, knowing when food trials are appropriate, and what new medications help make our patients comfortable! Tune in to learn how to put atopic dermatitis into remission!Sponsored By: Elanco

Please visit answersincme.com/CKC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evolving role of OX40/OX40L-targeted monoclonal antibodies (mAbs) for the treatment of moderate to severe atopic dermatitis.Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting OX40/OX40L in the treatment of moderate to severe atopic dermatitis (AD); Review the clinical profiles of OX40/OX40L-targeted monoclonal antibodies in treating moderate to severe AD; and Outline clinical considerations for the future integration of OX40/OX40L-targeted mAbs into treatment plans for moderate to severe AD.

Listen in as Evette Whaley and Katie Smiley PA-C talk about innovative strategies for NPs and PAs to improve treatment for pediatric patients with atopic dermatitis. They discuss how to assess the whole patient and their family to better understand the impact of the disease on their quality of life. They also discuss newer treatments and how they can be incorporated into a comprehensive management plan for pediatric patients and their caregivers. Presenters:Evette WhaleyCaregiverBaltimore, Maryland Katie Smiley PA-CGrants & Clinical DirectorProgram Coordinator, Multidisciplinary Atopic Dermatitis ProgramAllergy & Asthma Medical GroupRady Children's HospitalSan Diego, CaliforniaLink to full program:https://bit.ly/43svVyJ

With all these novel treatments for psoriasis and eczema available, how can your patients choose? Don't worry, we've got a plan. This week, we're joined by Dr. Peter Lio as he introduces ESTAR, a system to help patients choose medications. Listen in as he discusses a new paradigm to empower your patients and make choosing treatments a collaborative process. Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com.   Hear Dr. Lio live at IDS 2025 for a deep dive with fellow experts during the “Integrative Approach to Eczema” panel. View Agenda: https://bit.ly/42joj2r   Peter Lio, MD is a Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University. He received his medical degree from Harvard Medical School and his Dermatology training at Harvard. While at Harvard, he received formal training in acupuncture. Dr. Lio is the founding director of the Chicago Integrative Eczema Center and a founding faculty member of the Integrative Dermatology Certificate Program with over 400 publications and 4 textbooks.    

Diego Dasilva, MD, FAAD interviewed by Deirdre Hooper, MD, FAAD

This week's episode is a replay! We ran into some technical difficulties with a guest episode that was scheduled for this week (super excited about this guest) and will release at a later date. Stay tuned!So... you have ruled out flea and food allergy and now it is time for THE talk. The chronic, lifelong, multimodal therapy required atopic dermatitis talk? For such a common disease, how come this spiel can be so difficult? Check out this week's episode of The Derm Vet podcast for tips and tricks!TIMESTAMPSIntro 00:00Explaining Feline Atopic Skin Syndrome To Pet Owners 00:56The Reasoning For Atopic Dermatitis In Pets 05:04Explaining Multimodal Therapy To Pet Owners 11:08Outro 14:02

In this episode of Derms and Conditions, Dr James Q. Del Rosso welcomes back his longtime friend and pediatric dermatology expert, Dr Lisa Swanson. Together, they explore the rapidly evolving treatment landscape for pediatric atopic dermatitis, with a focus on newly approved non-steroidal topical therapies. Dr Swanson shares her insights on tapinarof 1% cream, now FDA-approved for patients as young as two years old, and topical roflumilast 0.15% cream, approved down to age six. The duo discusses how aryl hydrocarbon receptor (AhR) agonism makes tapinarof effective in both atopic dermatitis and psoriasis, likening its action to a “SNOO” that adjusts to soothe inflammation. They also dive into data from the ADORING 1 and ADORING 2 phase 3 trials, highlighting tapinarof's rapid reduction in itch and its positive impact on sleep—critical outcomes for both children and their parents. Dr Swanson offers real-world anecdotes about the sleep-depriving toll of pediatric eczema and how effective therapies can restore rest for the entire family. The conversation touches on skin of color considerations, including how atopic dermatitis may present differently and why diverse representation in clinical trials is essential. Dr Swanson underscores the importance of tactile assessments and shares practical pearls for evaluating eczema severity across skin types. Finally, they explore safety and tolerability, emphasizing tapinarof's low risk of systemic absorption, even in young children prone to thumb-sucking or hand-to-mouth behavior. Tune in for clinical pearls, new treatment insights, and a few laughs between two dermatology BFFs.

Join Dr. Renda Knapp, a board-certified OB/GYN, and Dr. Rachel Schultz, a pediatric specialist, as they tackle one of the most common skin conditions affecting infants: eczema (atopic dermatitis). In this informative podcast, our medical experts explain everything parents need to know about managing their baby's sensitive skin. This podcast offers practical guidance for daily management and long-term care. Whether you're a new parent noticing your baby's first patches of dry, irritated skin or looking for better ways to manage your child's established eczema, this podcast delivers compassionate, evidence-based advice to help your little one find relief. Subscribe for weekly episodes.

Join Prof. Lisa Beck as she explores the chronic and persistent burden of AD as well as the concept of early intervention.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.   Speaker disclosures: Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi.    © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2407353  – 1.0 – 02/2025 MAT-US-2501683 v1.0 - P Expiration Date: 02/24/2027

Teresa Wright, MD, FAAD, FAAP, joins host Dr. Edith Bracho-Sanchez to talk about eczema or atopic dermatitis, a common skin condition that causes dry, red, itchy rashes. They look at causes, treatments, tips to prevent flare-ups and whether the condition will improve as children get older.  

What's new in dermatology? DEF Advisory Council Members address some of the latest approvals and therapeutic updates of the past year. Hear from Joe Gorelick, MSN, FNP-C; Andrea Nguyen, DMSc, MPAS, PA-C; Kara Gooding, MMS, PA-C; and Alexa Hetzel, MS, PA-C, as they address new developments in atopic dermatitis, psoriasis, and hidradenitis suppurativa. Plus, winter skin care tips and a fresh take on JAK inhibitors from Brad Glick, DO, FAAD.Like what you're hearing? Want to learn more about the Dermatology Education Foundation? Explore assets and resources on our website.

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, welcomes E. James Song, MD, Chief Medical Officer at Frontier Dermatology, to explore the nuances of systemic therapy selection for atopic dermatitis (AD) and offer practical guidance on tailoring treatment plans to optimize outcomes for these patients. They begin by discussing the importance of considering patient-specific factors, such as contraindications, access, and age, when selecting among the 3 currently available biologics for AD: dupilumab, tralokinumab, and lebrikizumab. While these therapies share many similarities, nuanced differences—such as dupilumab's approval for younger patients and asthma comorbidity, or lebrikizumab's sustained efficacy after discontinuation—can guide treatment decisions. They also discuss adverse events, including conjunctivitis and dupilumab-associated facial erythema, highlighting strategies for managing these issues. Dr Song notes that switching within the IL-13 pathway can often resolve conjunctivitis and speculates on the possible mechanisms behind facial redness. They then explore one critical insight: the potential for patients to fail one biologic and still respond to another within the same class. While complete nonresponders may benefit from switching to a different class, such as JAK inhibitors, partial responders often do well with another IL-13 inhibitor. Tune in to the full episode to explore more insights on optimizing AD management, including how to navigate biologic options, manage adverse events, and approach challenging cases while embracing new therapies and tailoring care to each patient's unique needs.

On this episode, we evaluate the current guidelines and evidence-based treatment strategies for managing atopic dermatitis. We compare and contrast the efficacy, safety profiles, and appropriate use of various therapies. Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

Sponsored by Elanco. Unlike conventional treatments for canine allergic and atopic dermatitis, novel targeted therapies provide rapid relief with a reduced risk for adverse events. In this podcast, Andrew Rosenberg, DVM, and Adam Christman, DVM, MBA, react to the availability of a once-daily oral JAK inhibitor, highlighting it as a significant advancement in managing difficult skin conditions in dogs. Learning Objectives: Understand the various causes of canine allergic and atopic dermatitis. Gain insight into using available treatment options to manage canine allergic and atopic dermatitis. Learn how Zenrelia™ (ilunocitinib tablets) can be used to offer dogs relief from pruritus associated with allergic and atopic dermatitis.  DISCLAIMER Zenrelia, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-24-1649 INDICATIONS Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. IMPORTANT SAFETY INFORMATION Read the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.

Looking for an integrative approach to infant AD? We've got just the expert. This week, we're joined by Dr. Samantha Casselman as she helps us navigate how to work with concerned parents to improve their child's eczema. Listen in as she discusses the nuances of steroid phobia, how to create an eczema action plan, and how to best communicate with parents. Samantha Casselman, DNP CPNP-PC is a Pediatric Nurse Practitioner in Phoenix, AZ. She is practice owner of Happy Skin Pediatric Dermatology, where she specializes in infant and child atopic dermatitis. She is affiliated with the National Eczema Association and current executive board member of the National Association of Pediatric Nurse Practitioners.   This episode concludes Season 6. Thank you for tuning in! Season 7 begins March 13, 2025. For access to CE/CME courses year-round, become a member at LearnSkin.com.

A troubling disconnect between medical expertise and insurance mandates is putting patients' health at risk. Policies like step therapy and prior authorization are forcing individuals into treatments not recommended by their doctors—often with devastating consequences. In this episode, we hear from a patient who endured months of suffering due to her insurer's 'fail-first' requirements. We also talk with a doctor navigating this impossible system and a biotech leader fighting to ensure innovative treatments reach the patients who need them most. Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/

On this episode Lara and Vyanka talk to Prof Alan Irvine from St James's Hospital in Dublin all about the immunology of atopic dermatitis and eczema. This is ImmunoTea: Your Immunology Podcast, presented by Dr Lara Dungan and Dr Vyanka Redenbaugh. This is the show where we tell you all about the most exciting research going on in the world of immunology. So grab a cup of tea, sit down and relax and we'll fill you in. Contact us at ImmunoTeaPodcast@gmail.com or @ImmunoTea on twitter. Hosted on Acast. See acast.com/privacy for more information.

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, invites Peter Lio, MD, a clinical professor of dermatology at Northwestern University, to explore the complexities of selecting therapies for atopic dermatitis (AD) with a particular focus on the newly approved IL-13 inhibitor, lebrikizumab. With a growing number of treatment options, Dr Lio and Dr Del Rosso examine how these therapies are enhancing patient management in unique ways. The discussion opens with a look at the current "embarrassment of riches" in AD treatments. Dermatologists now have multiple biologic options to choose from, each with distinct features. Dr Lio highlights lebrikizumab's flexible dosing, which can shift to once monthly after the initial treatment period, potentially offering patients a more manageable treatment routine. They also explore key differences among IL-13 inhibitors, such as lebrikizumab's unique binding characteristics that may influence the overall balance of IL-13 in the body. Dr Lio also notes the possibility of achieving relative remission for certain patients on lebrikizumab, as suggested by a long-term extension study where some patients maintained improvement even after stopping the drug. They also cover the safety and tolerability aspects of AD therapies, including conjunctivitis, arthropathy, and erythematous reactions sometimes seen with these drugs. Dr Lio shares insights on managing these side effects, emphasizing that despite similar mechanisms of action, switching between IL-13 inhibitors may alleviate adverse reactions for certain patients. Tune in to the full episode for expert insights on differentiating and integrating the latest therapies for AD, strategies for engaging patients in their treatment plans, and valuable guidance on navigating today's expanding therapeutic landscape.

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Atopic Dermatitis (Eczema)⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠from the Dermatology section at ⁠⁠⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠ Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets

In today's VETgirl online veterinary CE podcast, we talk to Dr. Darren J Berger, DACVD on all things Canine Atopic Dermatitis (CAD). In veterinary medicine, we see atopy a ton, but we still see a lot of “failure” in treatment! Tune in to learn what we can do to better treat CAD, how to prevent our pet owners from getting so frustrated by it, and when to refer these cases to a dermatologist! Learn what your ultimate goal is in treating pruritic dogs, and what's the latest innovation in treating dogs with CAD!Sponsored By: Elanco

Hair loss can have many root causes for both men and women, but there are solutions! On this episode of Vitality Radio, Jared talks to Rosalynde Marchant from Hairs a Million about the products she developed post-chemo treatments to regrow her own hair. She's since been having incredible success sharing her products with people who are losing hair for a variety of reasons. Jared and Roz discuss how topical nutrients can regrow hair, but also how to deliver the body what it needs internally to ensure it has the nourishment it needs to grow healthy hair. Products:Hairsamillion Ridgecrest Herbals Hair ReViveAdditional Information:Code: haircombo - $10 off when you purchase the Hairs a Million serum along with Hair ReViveVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

Nemolizumab, pruritis, and Dr. Shawn Kwatra! - Food and atopic dermatitis - Dermasphere clip show: episodes 131-140! Find Dr. Shawn Kwatra on social media at DrShawnKwatra Want to donate to the cause? Do so here! Donate to the podcast: uofuhealth.org/dermasphere Check out our video content on YouTube: www.youtube.com/@dermaspherepodcast and VuMedi!: www.vumedi.com/channel/dermasphere/ The University of Utah's Dermatology ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare - ⁠ Connect with us! - Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: - ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge) - ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn more dermatology!

Peds derm discussions with Dr. Lisa Swanson! - Infant gut microbiota and risk for allergic disease - Maternal vitamin D and atopic dermatitis - Tocilizumab for H syndrome - Nadolol = or > propranolol for hemangiomas Lisa Swanson can be found at lisaswansonmd@gmail.com Want to donate to the cause? Do so here!Donate to the podcast: uofuhealth.org/dermasphereCheck out our video content on YouTube:www.youtube.com/@dermaspherepodcastand VuMedi!: www.vumedi.com/channel/dermasphere/The University of Utah's DermatologyECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -⁠ Connect with us!- Web: ⁠dermaspherepodcast.com/⁠ - X: @DermaspherePC- Instagram: dermaspherepodcast- Facebook: www.facebook.com/DermaspherePodcast/- Check out Luke and Michelle's other podcast,SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠Dermasphere has received an unrestricted educational grant from Incyte Corporation. Thanks, Incyte!Check out our friends at:- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)- ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learnmore dermatology!